References
- Adami HO, Bergstrom R, Mohner M, Zatooski W, Storm H, Ekbom A, Tretli S, Teppo L, Ziegler H, Rahu M, Gurevicius R, Asengrevics A. Testicular cancer in nine northern European countries. Int J Cancer 1994;59:33-8.
- Powles TB, Bhardwa J, Shamash J, Mandalia S, Oliver T. The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU Int 2005;95:1197-2000.
- Bosl GJ. Patil S. Carboplatin in clinical stage seminoma: Too much and too little at the same time. J Clin Oncol 2011;10:949-52.
- National Comprehensive Cancer Network v 2.2011. Clinical Practice Guidelines in Oncology. Testicular Cancer [displayed 29/08/2011]. Available at: http://www.nccn.org
- de Wit R, Fizazi K. Controversis in the management of clinical stage I testis cancer. J Clin Oncol 2006;24:5482-92.
- Oliver T. Conservative management of testicular germ-cell tumors. Nat Clin Pract Urol 2007;4:550-60.
- Warde P, Specht L, Horvich A, Oliver T, Panzarella T, Gospodarowicz M, von der Masse H. Prognostic factors for relapse in stage I seminoma managed by surveillance: A pooled analysis. J Clin Oncol 2002;20:4448-52.
- Cullen M, James N. Adjuvant therapy for stage I testicular cancer. Cancer Treat Rev 1996;22:253-64.
- Fossa S.D, Langmark F, Aass N, Andersen A, Lothe R, Borresen AL. Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br J Cancer 1990;61:639-43.
- Hamilton C, Horwich A, Easton D, Peckman MJ. Radiotherapy for stage I seminoma testis: Results of treatment and complications. Radiother Oncol 1986;6:115-20.
- Aass N, Grünfeld B, Kaalhus O, Fossa D. Pre-and posttreatment sexual life in testicular cancer patients: a descriptive investigation. Br J Cancer 1993;67:1113-7.
- Aaroson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Flecher H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Nation Cancer Inst 1993;85:365-76.
- Michelson H, Bolund C, Nilsson B, Brandberg Y. Health-related quality of life measured by the EORTC QLQ-C30. Acta Oncol 2000;39:477-84.
- Cox JD, Joann Stetz BS, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Rad Oncol Biol Phys 1995;31:1341-6.
- Oliver RTD, Mason MD, Mead GM, von de Maase H, Rustin GJS, Joffe KJ, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet 2005;366:293-300.
- Oliver RTD, Mead GM, Rustin GJS, Joffe KJ, Aass N, Coleman R, Gabe R, Polloch P, Stenning SP. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: Mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC30982 Study (ISRCTN27163214). J Clin Oncol 2011;29:957-62.
- Albers P. Management of stage I testis cancer. Eur Urol 2007;51:34-44.
- Fossa SD, Horwich A, Russel JM, Roberts JT, Cullen MH, Hodson NJ, Yosef H, Duchesne GM, Owen JR, Grosch EJ, Chetiyawardana AD, Reed NS, Widmer B, Stenning SP. Optimal planning target volume for stage I testicular seminoma: A medical research council randomized trial. J Clin Oncol 1999;17:1146-54.
- Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, Stenning SP. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: A report on medical research council trial TE18. European Organisation for the Research and Treatment Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005;23:1200-8.
- Hahn NM, Sweeney CJ. Germ cell tumors: An update of recent data and review of active protocols in stage I and metastatic disease. Urol Oncol 2005;23:293-302.
- Alomary I, Samant R, Genest P, Eapen L, Gallant V. The prefered treatment for stage I seminoma: A survey of Canadian radiation oncologists. Clin Oncol 2006;18:696-9.
- Dieckman KP, Beuggeboes B, Pichlmeier U, Kuster J, Mullerleile U, Bartels H. Adjuvant treatment of clinical stage I seminoma: Is a single course of carboplatin sufficient? Urology 2000;55:102-6.
- Aparico J, Germa JR, del Muro XG, Maroto P, Arranz JA, Saens A, Barnadas A, Dorca J, Guma J, Olmos D, Bastus R, Carles J. Almenar D, Sanchez M, Paz-Arez L, Satrustegui JJ, Mellado B, Balil A, Lopez-Brea M, Sanchez A. Riskadapted management for patients with clinical stage I seminoma: The second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 2005;23;8717-23.
- Powles T, Robinson D, Shamash J, Moller H, Tranter N. Oliver T. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 2008;19:443-7.
- Aparico J, del Muro XG, Maroto P, Paz-Arez L, Alba E, Sanchez A, Terrasa J, Barnadas A, Almenar D, Arranz JA, Sanchez M, Fernandez A, Sastre J, Carles J, Dorca J, Guma J, Yuste AL, Germa JR. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003;14:867-72.
- Hoffman EK, Chen MH, Punglia RS, Beard CJ, D'Amico AV. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol 2008;26;3937-42.
- Bieri S, Rouzaud M, Miralbell R. Seminoma of the testis: Is scrotal shielding necessary when radiotherapy is limited to para-aortic nodes? Radiother Oncol 1999;50:349-53.
- Majewski W, Majewski S, Maciejewski A, Kolosza Z, Tarnawski R. Adverse effects after radiotherapy for early stage (I, IIa, IIb) seminoma. Radiother Oncol 2005;76:257-63.
- Zadravec Zaletel L, Bratanic N, Jereb B. Gonadal function in patients treated for Hodgkin' disease in childhood. Radiol Oncol 2010;44:187-93.
- Martin JM, Panzarella T, Zwahlen DR, Chung P, Werde P. Evidence-based guidelinies for following stage 1 seminoma. Cancer 2007;109:2248-56.
- Arai Y, Kawakita M, Okada Y, Yoshida O. Sexuality and fertility in long-term survivors of testicular cancer. J Clin Oncol 2007;15;1444-8.
- van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyan R, Eliel MR, van Kerkhoff EHM, Delemarre JFM, Somers R. Second cancer risk following testicular cancer: A follow-up study of 1,909 patients. J Clin Oncol 1993;11:415-24.
- van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MWJ, Ribot JG, Hoestra HJ, Ouwens GM, Aleman BMP, van Leeuwen FE. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25:4370-8.
- Gamulin M, Kopjar N, Grgić M, Ramić S, Viculin T, Petković M, Garaj-Vrhovac V. Cytogenetic follow-up in testicular seminoma patients exposed to adjuvant radiotherapy. Coll Antropol 2010;34:455-65.
- Reiker PP, Edbril AD, Garnic MB. Curative testis cancer therapy: Psychosocial sequelae. J Clin Oncol 1985;3:1117-26.
- Dahl AA, Haaland CF, Mykletun A, Bremnes R, Dahl O, Klepp O, Wist E, Fossa SD. Study of anxiety disorder and depression in long-term survivors of testicular cancer. J Clin Oncol 2005; 23;2389-95.